RhumbLine Advisers
ORIC icon

RhumbLine Advisers’s Oric Pharmaceuticals ORIC Stock Holding History

RhumbLine Advisers’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1M Buy
79,063
+1,357
+2% +$15.4K ﹤0.01% 2198
2025
Q4 		$636K Sell
77,706
-4,325
-5% -$49.8K ﹤0.01% 2519
2025
Q3 		$984K Buy
82,031
+10,600
+15% +$112K ﹤0.01% 2251
2025
Q2 		$725K Sell
71,431
-17,322
-20% -$116K ﹤0.01% 2425
2025
Q1 		$495K Sell
88,753
-4,566
-5% -$39.9K ﹤0.01% 2582
2024
Q4 		$753K Buy
93,319
+4,072
+5% +$37.4K ﹤0.01% 2403
2024
Q3 		$915K Sell
89,247
-3,455
-4% -$34.2K ﹤0.01% 2308
2024
Q2 		$655K Buy
92,702
+32,402
+54% +$290K ﹤0.01% 2476
2024
Q1 		$829K Buy
60,300
+2,396
+4% +$28.5K ﹤0.01% 2356
2023
Q4 		$533K Sell
57,904
-677
-1% -$4.89K ﹤0.01% 2623
2023
Q3 		$354K Buy
58,581
+6,676
+13% +$54.7K ﹤0.01% 2831
2023
Q2 		$403K Buy
+51,905
New +$295K ﹤0.01% 2828
2022
Q2 		– Sell
-38,871
Closed -$208K – 3196
2022
Q1 		$208K Buy
38,871
+2,921
+8% +$26.3K ﹤0.01% 2749
2021
Q4 		$528K Sell
35,950
-402
-1% -$6.27K ﹤0.01% 2487
2021
Q3 		$760K Buy
36,352
+2,578
+8% +$52.3K ﹤0.01% 2352
2021
Q2 		$597K Buy
33,774
+11,287
+50% +$247K ﹤0.01% 2487
2021
Q1 		$551K Buy
22,487
+495
+2% +$15.6K ﹤0.01% 2445
2020
Q4 		$744K Buy
21,992
+13,308
+153% +$382K ﹤0.01% 2267
2020
Q3 		$217K Sell
8,684
-1,425
-14% -$33.9K ﹤0.01% 2652
2020
Q2 		$341K Buy
+10,109
New +$323K ﹤0.01% 2519

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RhumbLine Advisers's ORIC Position: Q1 2026 in Review

RhumbLine Advisers increased its Oric Pharmaceuticals (ORIC) stake by 1.7% in Q1 2026, buying an estimated $15.4K and bringing the position to 79,063 shares worth $1M. The position accounts for ﹤0.01% of the portfolio, ranked #2198.

RhumbLine Advisers first reported a position in ORIC in Q2 2020 and has held it in 20 quarters since. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • RhumbLine Advisers held 79,063 shares of Oric Pharmaceuticals worth $1M as of Q1 2026.
  • RhumbLine Advisers bought 1,357 Oric Pharmaceuticals shares in Q1 2026, an estimated $15.4K.
  • Oric Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2198 holding.
  • RhumbLine Advisers first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 20 quarters since.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.